globenewswire news

EssilorLuxottica: Disclosure of transactions in own shares

2026-09-07T16:00:00Z

Disclosure of transactions in own shares

Paris, France (September 7, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 28, 2026, EssilorLuxottica declares that from August 31, 2026, to September 3, 2026, inclusive, the following share buybacks were carried out:

Name of the issuer	Identity code of the issuer	Day of the transaction	Identity code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares (€) *	Market (MIC Code)
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	31/08/2026	FR0000121667	11,955	160.0000	XPAR
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	31/08/2026	FR0000121667	3,464	160.0000	CEUX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	31/08/2026	FR0000121667	106	160.0000	TQEX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	31/08/2026	FR0000121667	62	160.0000	AQEU
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	01/09/2026	FR0000121667	89,680	159.4859	XPAR
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	01/09/2026	FR0000121667	39,072	159.4114	CEUX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	01/09/2026	FR0000121667	5,787	159.4871	TQEX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	01/09/2026	FR0000121667	7,983	159.4951	AQEU
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	02/09/2026	FR0000121667	160,350	158.8454	XPAR
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	02/09/2026	FR0000121667	60,550	158.7640	CEUX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	02/09/2026	FR0000121667	9,150	158.7112	TQEX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	02/09/2026	FR0000121667	13,400	158.7329	AQEU
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	03/09/2026	FR0000121667	16,111	157.6273	XPAR
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	03/09/2026	FR0000121667	4,657	157.4573	CEUX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	03/09/2026	FR0000121667	957	157.5571	TQEX
ESSILORLUXOTTICA SA	549300M3VH1A3ER1TB49	03/09/2026	FR0000121667	1,397	157.6009	AQEU
			TOTAL	424,681	159.0096

* Rounded to four decimal places

Attachment

DOWNLOAD THE PRESS RELEASE

Articles

IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2025

2026-09-07T16:00:00Z

Aggregated presentation by day and by market

EssilorLuxottica: Disclosure of transactions in own shares

2026-09-07T16:00:00Z

Disclosure of transactions in own shares

Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)

2026-09-07T15:00:00Z

Company announcement No. 46 / 2026

Peptides Canada Reports Growing Research Demand for Retatrutide Amid Expansion of Domestic Peptide Supply Market

2026-09-07T13:28:08Z

Vancouver, BC, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Peptides Canada, a domestic supplier of research-grade peptide compounds, today highlighted continued growth in demand for metabolic research peptides, including retatrutide, as...

Novo Nordisk A/S - share repurchase programme

2026-09-07T11:12:52Z

Bagsværd, Denmark, 07 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament...

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

2026-09-07T11:00:00Z

COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026,...

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification

2026-09-07T10:00:00Z

Data highlights

Virbac : Declaration of the number of shares and voting rights 08/2026

2026-09-07T08:44:58Z

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

Virbac : Declaration of the number of shares and voting rights 07/2026

2026-09-07T08:39:42Z

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

Teva Announces Launch of Offering of Senior Notes

2026-09-07T07:53:21Z

TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose...

Clariane has launched a proposed offering of €500 million of senior notes to refinance part of its existing indebtedness

2026-09-07T07:40:40Z

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE...

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

2026-09-07T07:00:16Z

COPENHAGEN, Denmark, September 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares...

Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a Novel Inhaled Therapy for Chronic Respiratory Diseases

2026-09-07T01:19:25Z

ZHUHAI, China, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Rezubio today announced that it has successfully completed dosing of the first cohort in its Phase 1 clinical trial following clearances from the...

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

2026-09-06T05:00:00Z

BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat...

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026

2026-09-06T05:00:00Z

WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today...

The International Myeloma Foundation Mourns the Passing of Former IMF Board Member Dr. Robert A. Kyle — The Father of Multiple Myeloma

2026-09-04T22:34:07Z

STUDIO CITY, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- It is with great sadness that the International Myeloma Foundation (IMF) shares news of the passing of Dr. Robert A. Kyle...

Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference

2026-09-04T22:32:51Z

Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as...

Conavi Medical Announces Media and Digital Marketing Agreements

2026-09-04T22:02:58Z

TORONTO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies...

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

2026-09-04T21:00:00Z

BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on August 31, 2026, it received a notice (the “Notice”)...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-09-04T20:30:00Z

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of...

Bright Minds Biosciences to Present at Upcoming Conferences

2026-09-04T20:30:00Z

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists...